Predicting Cognitive Decline in Subjects at Risk for Alzheimer Disease by Using Combined Cerebrospinal Fluid, MR Imaging, and PET Biomarkers

Abstract

For the Alzheimer's Disease Neuroimaging InitiativePurpose:To assess the extent to which multiple Alzheimer disease (AD) biomarkers improve the ability to predict future decline in subjects with mild cognitive impairment (MCI) compared with predictions based on clinical parameters alone. Materials and Methods:All protocols were approved by the institutional review board at each site, and written informed consent was obtained from all subjects. The study was HIPAA compliant. Alzheimer's Disease Neuroimaging Initiative (ADNI) baseline magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) studies for 97 subjects with MCI were used. MR imaging-derived gray matter probability maps and FDG PET images were analyzed by using independent component analysis, an unbiased data-driven method to extract independent sources of information from whole-brain data.The loading parameters for all MR imaging and FDG components, along with cerebrospinal fluid (CSF) proteins, were entered into logistic regression models (dependent variable: conversion to AD within 4 years). Eight models were considered, including all combinations of MR imaging, PET, and CSF markers with the covariates (age, education, apolipoprotein E genotype, Alzheimer's Disease Assessment Scale-Cognitive subscale score). Results:Combining MR imaging, FDG PET, and CSF data with routine clinical tests significantly increased the accuracy of predicting conversion to AD compared with clinical testing alone. The misclassification rate decreased from 41.3% to 28.4% (P , .00001). FDG PET contributed more information to routine tests (P , .00001) than CSF (P = .32) or MR imaging (P = .08). Conclusion:Imaging and CSF biomarkers can improve prediction of conversion from MCI to AD compared with baseline clinical testing. FDG PET appears to add the greatest prognostic information.q RSNA, 2012 Supplemental material: http://radiology.rsna.org/lookup /suppl

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

“…This is in line with published evidence, e.g. the assessment of a panel of biomarkers combined instead of a biomarker alone (whatever it is) drastically increases the diagnostic accuracy in MCI and AD patients [7][8][9][10]24,43].…”

“…Some structured programs are currently ongoing where MCI patients are assessed by traditional clinical assessment supported by an extended range of core biomarkers that include MTA, CSFAb/tau, and hypometabolism on FDG-PET [7][8][9][10]. However, these programs are constrained to a limited number of academic memory clinics, whereas the measurement of individual biomarkers are now available to and used by a much larger number of memory clinics with a clinical research background, including those of the European Alzheimer's Disease Consortium (EADC, http://www.eadc.…”

Characterizing Gene and Protein Crosstalks in Subjects at Risk of Developing Alzheimer’s Disease: A New Computational Approach

“…For our predictive study, we utilized the dataset from an earlier study by Shaffer et al [52] based on ADNI-1. That particular study identified 97 MCI patients and predicted progression to AD dementia based on their clinical parameters, MRI results, PET scans, cerebrospinal fluid (CSF) markers (tau, p-tau181P, and β-amyloid1-42), the APOE ε4 genotype, and results from at least one follow-up clinical examination.…”

New Frontiers in Alzheimer's Disease Diagnosis

“…Since the complexity of this scenario impairs the use of current diagnostic tools for a correct data interpretation, in the recent years, new strategies such as the integrated and combined use of neuropsychological profiles, imaging and biological fluids biomarkers have been developed, improving current diagnosis classification [9][10][11] and predicting the conversion from MCI to AD [12,13].…”